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Intraocular Pressure after Implantation of the Visian
Implantable Collamer Lens With CentraFLOW
Without Iridotomy
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! PURPOSE: To compare the intraocular pressure (IOP)
values during a 3-month period after implantation of
the new Visian Implantable Collamer Lens (ICL;
STAAR Surgical Company, Nidau, Switzerland) V4c
design with CentraFLOW technology without iridotomy
using a standard procedure followed by implantation of
the conventional ICL V4b model.
! DESIGN: Retrospective cohort study.
! METHODS: This study included 17 eyes implanted with
the ICL V4b model and 18 eyes implanted with the ICL
V4c model. The mean preoperative spherical equivalent
refractions were L7.48 ± 5.00 diopters and L8.66 ±
4.2 diopters, respectively. We compared the best-
corrected distance visual acuity before surgery with the
uncorrected distance visual acuity after surgery. The
intraocular pressure (IOP) was measured 1 week,
1 month, and 3 months after surgery. The central vault
at 3 months was measured using optical coherence tomog-
raphy.
! RESULTS: Threemonths after surgery, themean uncor-
rected distance visual acuities were L0.09 ± 0.12 loga-
rithm of the minimal angle of resolution units with the
V4b and L0.07 ± 0.11 logarithm of the minimal angle
of resolution units with the V4c. The mean distances
between the ICL and the anterior crystalline lens surface
were 557 ± 224 mm and 528 ± 268 mm for the V4b and
V4c, respectively (P[ .73). After 1 week and 1 month,
the mean IOPs were 13.7 and 13.3 mm Hg and 14.7 and
15.1 mm Hg, respectively. There were no significant
differences in IOP within or between groups during the
follow-up period (P> .05, for all comparisons).
! CONCLUSIONS: The new ICL with the CentraFLOW
design seems to provide similar results as its predecessors
for the correction of moderate to high myopia and main-
tenance of safe IOP levels without iridotomy. (Am J
Ophthalmol 2013;156:800–805. ! 2013 by Elsevier
Inc. All rights reserved.)
P
HAKIC INTRAOCULAR LENSES (PIOLS) OF DIFFERENT
designs and materials have been developed as valu-
able alternatives to corneal refractive surgery.
Although a number of pIOL designs and modifications
have been implemented worldwide, the United States
Food and Drug Administration has approved only 2 pIOLs:
the anterior chamber iris-fixated Artisan/Verisyse pIOL
(Ophtec BV, Groningen, The Netherlands/AMO, Santa
Ana, California, USA)1,2 that was approved in 2004 and
the posterior chamber Visian Implantable Collamer
Lens (Visian ICL; STAAR Surgical Company, Nidau,
Switzerland) that was approved in December 2005.2 The
Visian ICL has been reported to be a valuable surgical
option to treat various degrees of ametropia.3 Two pIOLs
currently are undergoing Food and Drug Administration
phase 3 clinical trials: the iris-fixated anterior chamber
Veriflex/Artiflex (Ophtec BV/AMO) and the angle-
supported AcrySof Cachet anterior-chamber pIOL (Alcon
Laboratories, Inc, Fort Worth, Texas, USA). Recent
studies have shown that the latter pIOL had an acceptable
safety profile in patients with myopia. However, potential
complications such as long-term endothelial cell loss are
a concern. Oversizing of the pIOL can produce excessive
vaulting and rapid endothelial cell loss when the internal
diameter of the anterior chamber is not well correlated
with the white-to-white values.4 Elevated intraocular pres-
sure (IOP) is a potential adverse event associated with
anterior chamber pIOLs.5 The Visian ICL is a posterior
chamber pIOL manufactured by Staar Surgical Company
and has been reported as a valuable surgical option to treat
ametropia of various refractive ranges.2
Recently, a new type of Visian ICL has been developed:
the Visian ICL V4c with CentraFLOW technology. A
central artificial hole called the KS-AquaPORT was added
to the center of the ICL optic to improve aqueous humor
circulation in the eye. This new development eliminates
the need for a preoperative peripheral laser iridotomy or
intraoperative peripheral iridectomy, which simplifies
the surgical procedure and significantly reduces the
complications associated with iridotomy such as hyphema,
inflammation, or vitreous and rhegmatogenous retinal
detachment.6–9 Moreover, uneventful preoperative laser
iridotomy may develop a postoperative pupillary block if
residual viscoelastic blocks the normal aqueous humor
flow or because of closure of a previously patent
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iridotomy. However, it is necessary to evaluate the impact
of this new surgical approach on elevations in IOP in the
immediate and intermediate postoperative periods, which
depend on the physical relationship between the IOL
implant, the crystalline lens, and the iris, among other
factors.
Earlier studies have evaluated the distance between the
ICL and the crystalline lens using ultrasound bio-
microscopy,10 Scheimpflug photography,11 or the first
generations of spectral-domain optical coherence tomog-
raphy (OCT) technology.12 New Spectralis OCT (Heidel-
berg Engineering, Heidelberg, Germany) with an anterior
segment module offers image acquisition of the anterior
chamber and provides high-resolution measurements of
the distance between the posterior ICL surface and the
anterior crystalline lens pole. This distance, referred to as
vault, is the most important issue involved in ICL-
induced complications, such as pupillary block13 and cata-
ract formation.14 Ongoing concerns exist about the risk of
late-onset cataract formation, presumably resulting from
direct physical contact between the ICL and the crystalline
lens, and disruptions in aqueous flow that interfere with
lens nutrition and cause metabolic disturbances in the crys-
talline lens.15 The new Visian ICL V4c with CentraFLOW
was developed to eliminate such disadvantages. The
purpose of the current study was to compare the clinical
outcomes with the Visian ICL V4c design with Centra-
FLOW technology without the need for a peripheral iridot-
omy with the conventional model V4b.
METHODS
THE STUDY PROTOCOL WAS REVIEWED AND APPROVED BY
the Ethics Committee of Hospital Universitario Morales
Meseguer, Murcia, Spain, and was in agreement with the
standards of clinical practice and national and interna-
tional guidelines. Following the tenets of the Declaration
of Helsinki, patients were informed about the surgical
details and provided written informed consent.
This study included 17 eyes of 9 patients implanted with
the Visian ICL V4b model and 18 eyes of 10 patients
implanted with the new Visian ICL V4c model at Clı´nica
Novovisio´n Dr Ramo´n Gutie´rrez, Murcia, Spain, from
September 2011 through April 2012. Complete ophthal-
mologic examinations were performed that included mani-
fest and cycloplegic refractions, keratometry and corneal
topography with the Pentacam (Oculus Optikgera¨te
GmbH, Wetzlar, Germany), Goldmann applanation
tonometry, and binocular indirect ophthalmoscopy
through dilated pupils.
The inclusion criteria for ICL implantation were age
between 20 and 45 years, a stable refractive error during
the previous 18 months, and a preoperative spectacle
spherical power between "3 and "15 diopters (D). The
exclusion criteria included anterior chamber depth of less
than 2.8 mm, a history of glaucoma or ocular inflammation,
pre-existing corneal disease, and endothelial cell density of
less than 2500 cells/mm.2
! IMPLANTABLE COLLAMER LENS SELECTION AND CHAR-
ACTERISTICS: The one-piece ICL pIOL is made of
collamer, a hydrophilic material composed of collagen
and poly-hydroxyethyl methacrylate-based copolymer.
The lens is available in spherical powers ranging
from "3.0 to "23.0 D and astigmatic corrections of 1.0
to 6.0 D. The lens size was defined using the manufacturer
calculator software according to the horizontal white-to-
white distance obtained by partial coherence interferom-
etry (IOLMaster; Carl Zeiss Meditec, Jena, Germany).
Two subsequent groups were formed with the last ICL
V4b model for myopic correction and the first ICL V4c
model implanted. Patients scheduled for intraocular refrac-
tive surgery from September 2011 through May 2012 were
enrolled in this trial. The preoperative demographics of the
study population are shown in the Table.
! VAULT ASSESSMENT WITH SPECTRAL-DOMAIN
OPTICAL COHERENCE TOMOGRAPHY: A Spectralis SD-
OCT (Heidelberg Engineering, Heidelberg, Germany)
with the anterior segment module was used to acquire
images of the anterior chamber; a detailed view of the
TABLE. Preoperative Patient Demographics in Eyes
Undergoing Visian Implantable Collamer Lens Implantation
with CentraFLOW (ICLV4c) and without CentraFLOW
(ICL v4b)
Parameter ICL V4b ICL V4c P Value
No. of eyes 17 18
Gender
Male 8 (47%) 3 (17%)
Female 9 (52%) 15 (83%)
Age (y) 32.6 6 7.2 34.5 6 9.5 .48
Range 26 to 45 26 to 50
Manifest refraction (D)
Sphere "7.95 6 3.77 "7.68 6 3.7 .938
Range "3.25 to "15.25 "1.75 to "17.25
Cylinder "1.51 6 1.13 "1.81 6 1.33 .578
Range 0.00 to "3.50 "0.50 to "5.50
ACD (mm) 3.43 6 0.37 3.25 6 0.18 .09
Range 2.8 to 3.91 2.98 to 3.52
WTW (mm) 12.15 6 0.75 11.96 6 0.4 .68
Range 11.09 to 13.60 11.25 to 12.63
ICL design
ICM 9 (53%) 11 (61%)
TICM 8 (47%) 7 (39%)
ACD ¼ anterior chamber depth; D ¼ diopter; ICL ¼ Implant-
able Collamer Lens; ICM ¼ ICL for myopia; TICM ¼ lens for
myopia with astigmatism; WTW ¼ white-to-white distance.
Data are mean 6 standard deviation unless otherwise
indicated.
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ICL and its relationship with intraocular structures was
obtained at the 3-month visit (Figure 1). The same
observer performed all OCT examinations and vault
measurements to determine accurately the implant posi-
tion in relation to the crystalline lens. OCT was performed
under low light conditions, and no pharmacologic agents
were used. A fixation light was used for the fellow eye to
maintain a fixed amount of accommodation.
! SURGICAL TECHNIQUE: Two neodymium:yttrium–
aluminum–garnet laser iridotomies were created at the
10- and 2-o’clock positions 2 weeks before surgery in the
ICL V4b group. No iridotomies were performed in the
ICL V4c group.
The same surgeon (R.G.-O.) performed all surgeries
uneventfully under topical anesthesia (1% lidocaine).
After creating a 3.2-mm clear corneal incision at the steep-
est meridian, the ICL was inserted with an injector
(STAAR Surgical Co.) into the anterior chamber that
previously was filled with sodium hyaluronate viscoelastic
(Provisc; Alcon Laboratories, Inc). The footplates were
placed behind the iris using a fine spatula. Viscoelastic
was replaced by balanced salt solution. The wound was
closed by stromal hydration after 1 mg cefuroxime sodium
was injected into the anterior chamber.16 The postopera-
tive therapy included topical moxifloxacin hydrochloride
(Vigamox; Alcon Laboratories Inc) 4 times daily for
1 week and dexamethasone (Dexafree; Thea Laboratories,
Barcelona, Spain) tapered over 5 weeks.
Postoperative examinations of the uncorrected distance
visual acuity, best-corrected distance visual acuity
(CDVA), manifested refraction, Goldmann applanation
tonometry, and anterior chamberOCTvaultwere performed
on day 1, week 1, and months 1 and 3. A subjective evalua-
tionof the presenceof halos anddysphotopsiawas carried out
by asking the patients and recorded as yes or no.
! STATISTICALANALYSIS: The SnellenVAwas converted
to the logarithm of the minimal angle of resolution values.
Statistical analysis was performed using SPSS for Windows
software version 19.0 (SPSS, Inc, Chicago, Illinois, USA).
Descriptive statistics were obtained. The normality of data
distribution of the measured outcomes was tested using the
Shapiro-Wilk test. For all statistical tests, a P value of less
than .05 was considered significant. The independent
samples Mann–Whitney U test was used to compare the
postoperative visual function between the 2 groups. Statis-
tical comparisons between the preoperative and postopera-
tive IOP values in each group were carried out using
a repeated measures analysis of variance with post hoc
correction (Bonferroni) for multiple comparisons. The
independent samples t test was used to compare the postop-
erative IOP values and vault readings between the groups.
RESULTS
! REFRACTIVE AND VISUAL OUTCOMES: The postopera-
tive spherical equivalent refractions were "0.2 6 0.4
and "0.3 6 0.5 for the V4b and V4c groups, respectively.
At 3 months, the respective mean uncorrected distance
visual acuity was "0.09 6 0.12 logarithm of the minimal
angle of resolution units in the V4b group and "0.07 6
0.11 logarithm of the minimal angle of resolution units in
the V4c group (P ¼ .43); 15 (88.2%) and 17 (94.4%) of
the eyes, respectively, achieved the same or superior uncor-
rected distance visual acuity after surgery compared with
the preoperative CDVA. Only 1 (5.9%) eye in the V4b
group did not achieve the desired target refraction; all
patients in the V4c group were within6 0.5 D of the target
refraction.
Overall, the CDVA improved at all follow-up visits in
9 (52.9%) of theV4b group and 8 (44.4%) of theV4c group.
The CDVAwas similar in 6 (35.3%) of the V4b group and 9
(50.0%) of the V4c group. A decrease of CDVAoccurred in
only 2 (11.8%) of eyes in the V4b group and in 1 (5.6%) eye
in the V4c group. There were no significant (P ¼ .81)
FIGURE1. Representative Spectralis anterior segment optical coherence tomography images of the distance between the Implantable
Collamer Lens (ICL; STAAR Surgical Company) and the anterior lens surface (vault) for the ICL (Top) without a central hole and
(Bottom) with CentraFLOW.
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differences between groups. A subjective assessment of
patient satisfaction showed that 5 patients reported halos
in the V4c group, which decreased 1 month after surgery.
! VAULT MEASUREMENT: At 3 months, the mean vault
was 557 6 224.4 mm (95% confidence interval, 442 to
672 mm) in the V4b group and 5286 268 mm (95% confi-
dence interval, 354 to 635 mm) in the V4c group; this
difference did not reach significance (P ¼ .73; Figure 2).
There was no correlation between age and vault value in
the V4b group (Pearson r, "0.244; P ¼ .16) or the V4c
group (Pearson r, "0.16; P ¼ .95).
! INTRAOCULARPRESSUREMEASUREMENT: Weobserved
a mild and transient increase in IOP during the first month;
however, no chronically elevated IOP levels or pupillary
block were observed in any group. The mean preoperative
IOP values were 11.5 6 2.8 mm Hg in the V4b group and
11.96 2.7 mmHg in the V4c group (P¼ .66). At 3 months,
the mean IOPs were 12.46 1.8 mmHg and 13.86 2.2 mm
Hg in the V4b and V4c group, respectively (Figure 3). There
were no significant differences in the mean IOP within each
group during the follow-up period (F ¼ .49, P ¼ .64) or
between groups at any follow-up visits (P > .05, for all
comparisons).
DISCUSSION
ICL IMPLANTS EFFECTIVELY CORRECT MODERATE TO HIGH
myopia, which has been widely reported in the literature.1,2
The current study found comparable visual and refractive
outcomes between both ICLs models, with no differences
in postoperative refraction or accuracy of the refractive
results between the 2 groups throughout the 3-month
follow-up period. The efficacy of the procedure was slightly
better in the V4c group, with 94.4% and 88.2% of eyes
having an uncorrected visual acuity equal or superior to
the preoperative CDVA in the V4c and V4b group, respec-
tively.
Regarding the optical performance of the new ICL with
CentraFLOW, although we have not evaluated the change
in the higher-order aberrations (HOAs) between the 2
groups, we recorded temporary halos in the V4c group
based on the subjective patient assessment. Induced nega-
tive spherical aberration and increased trefoil have been
reported after ICL implantation.17 Other studies have re-
ported that the ICL is at least as effective as excimer laser
intervention even in patients with a low spherical equiva-
lent refraction, with significantly lower induced spherical
aberrations after ICL implantation compared with laser
in situ keratomileusis.18 Subjective visual symptoms, such
as glare or halo, have been reported to be common in
the early postoperative period in conventional ICL-
implanted eyes. Regarding the new ICL with the central
hole, the presence of the central hole may deteriorate the
performance of the ICL to some extent and may induce
glare or halos. An animal model19 and in vitro optical
simulation studies20 have reported small and clinically
negligible differences between both types of ICLs. In the
FIGURE 2. Box-and-whisker plot showing the distance
between the Implantable Collamer Lens (ICL; STAAR Surgical
Company) without a central hole (ICL V4b) and with Centra-
FLOW (ICL V4c). At 3 months, the mean vault was 557 ±
224 mm in the ICL V4b group and 528 ± 268 mm in V4c group
with no significant differences between groups (P[ .73).
FIGURE 3. Graph showing intraocular pressure (IOP) levels
before and after implantation of the Implantable Collamer
Lens (ICL; STAAR Surgical Company) without a central
hole (ICL V4b) and with CentraFLOW (ICL V4c). At
3 months, the mean IOP was 12.4 ± 1.8 mm Hg and 13.8 ±
2.2 mm Hg in the ICL V4b and ICL V4c groups, respectively.
There were no significant differences in the mean IOP within
each group during the follow-up period (F [ 0.49, P [ .64)
or between groups at any time during the follow-up period
(P> .05, for all comparisons).
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current study, patient reports of halos in the V4c group
significantly decreased 1 month after surgery; however,
scattering and HOAs should be investigated in future
studies. The complaints about halos have been transient
in these patients, suggesting an adaptation process to the
presence of the ICL. Considering the small sample size, it
is impossible to evaluate potential relationships between
the optical power of the lens or potential positioning issues,
which may help to explain these photic phenomena.
Although HOAs might have some correlation with halos
as we found in patients who underwent laser in situ kerato-
mileusis,21 weak correlations were found in those patients
whose optical quality clearly was altered by corneal abla-
tion, and we did not expect that this would explain the
phenomena in patients with an ICL in whom HOAs
with previous types of lenses have caused much fewer
changes compared with ablative procedures. As a result,
we should not expect significant changes in contrast sensi-
tivity function considering the good optical quality associ-
ated with ICL implantation.17,18 Nevertheless, the current
data did not allow us to ignore the potential impact of
HOAs on the development of halos.
Conventional ICL implantation requires preoperative
laser iridectomies or intraoperative peripheral iridectomy
to prevent pupillary block. Neodyium:yttrium–aluminum–
garnet laser iridotomy carries the potential risk of intraoc-
ular complications such as hyphema, marked inflammation,
elevated IOP, chronic pigment dispersion, posterior syne-
chiae, and vitreous and rhegmatogenous retinal detach-
ments.22,23 Significant reductions of these complications
may be expected with the new ICL with the central
hole, which eliminates the need for neodyium:yttrium–
aluminum–garnet iridotomy or peripheral iridectomy
before implantation of the ICL and the potential
complications associated with these procedures. Acute
pupillary block, which frequently is associated with
inadequate preoperative iridotomies,22 currently is
managed by enlargement of existing iridotomies or creation
of additional peripheral iridectomies and may be avoided
using the new V4c design.
Development of anterior subcapsular opacities and clin-
ically relevant cataract remain major concerns in ICL
implantation. The main theories of the cause of this cata-
ract development are the absent or lower vault and the
tendency of the vault to decrease over time, causing
constant or intermittent contact between the ICL and
crystalline lens. Studies that evaluated the pathophysio-
logic features of anterior subcapsular cataracts secondary
to ICL implantation confirmed that contact with or close
proximity of the phakic lens to the crystalline capsule
might have disrupted the aqueous flow, which may have
led to metabolic changes and transformations within the
crystalline lens.15 The ideal postoperative vault must
create a space over the entire anterior crystalline lens
surface, with the recommended amount of vault equal to
1.0 to 1.5 central corneal thicknesses on slit-lamp exami-
nation.24 Poor vault (<250 mm) increases cataract devel-
opment, but excessive vault (>750 mm) can cause angle
closure, pupillary block, and glaucoma. Vaulting of the
ICL is affected by the ICL shape (ie, the V4 model was
an improved version of the flatter V3 previous design),6
white-to-white measurement,25 and age.11 To demon-
strate the safety of the new ICL design, it was important
to determine if vault values were comparable with the
classical ICL model. With spectral-domain OCT, 2-
dimensional and high-resolution images of the anterior
ocular segment can be obtained rapidly and with noncon-
tact procedures.12 It has been useful to elucidate the corre-
lation between the ICL and adjacent intraocular
structures and helpful to evaluate surgical procedures
and their potential complications.26 Regarding vaulting,
the current study found no significant differences between
the ICLs, which led us to believe that both lenses have
a similar anatomic interaction with the intraocular struc-
tures. This finding also may indicate that the central hole
contributes to improved circulation of the aqueous humor
to the anterior surface of the crystalline lens and therefore
prevents cataract formation. However, the short follow-up
in this small number of the patients is insufficient for
detecting such complications; longer follow-up with
more patients is required to obtain longer-term safety
data for the new ICL design.
We found no significant increases in IOP (including
pupillary block) throughout the 3-month observation
period or significant differences between the groups.
Thus, despite the absence of peripheral iridotomy, normal
aqueous flow seems to occur as a result of the central hole
in the new ICL V4c, which maintained in physiologic
IOP levels during the follow-up period in both groups.
Most studies have reported increased IOP levels after ICL
implantation, suggested to be a potential cause of pupillary
block, pigment dispersion, and steroid use.22 Spectral-
domain OCT images showed ICL-iris contact in both
groups, but the authors did not observe the potential
pigmentary dispersion previously observed with this refrac-
tive procedure. Other authors suggested that the soft hydro-
philic surface of the posterior chamber phakic IOL is
similar to the anterior capsule of the crystalline lens and
may prevent a mechanical loss of pigment.27
In summary, the current study showed the 3-month
safety and efficacy of the new ICL V4c with CentraFLOW
design. Although longer observation in a large number of
patients is required to assess the long-term safety of this
surgical procedure, clinically, the new model did not differ
in its intraoperative properties or postoperative follow-up
from those of the conventional ICL. We concluded that
the visual results, vault measurements, and IOP levels
were comparable in both groups. Another advantage was
that iridotomies were not needed because of the new ICL
V4c design.
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